Amgen Inc. v. Sanofi
Certiorari Denied
Petition for certiorari denied on January 7, 2019.
Issue
Whether the standard for determining the adequacy of the "written description of the invention" in a patent must be "in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains . . . to make and use the same," as stated within the Patent Act, 35 U.S.C. § 112(a), or whether court-created standards should control instead.
May 11, 2018Application (17A1262) to extend the time to file a petition for a writ of certiorari from May 24, 2018 to July 23, 2018, submitted to The Chief Justice.
May 14, 2018Application (17A1262) granted by The Chief Justice extending the time to file until July 23, 2018.
Jul 23, 2018Petition for a writ of certiorari filed. (Response due August 27, 2018)Aug 27, 2018Brief amici curiae of Bristol-Myers Squibb Company, Morphosys AG, Bavarian Nordic A/S, and UCB Biopharma SPRL filed.Sep 12, 2018DISTRIBUTED for Conference of 10/5/2018.
Sep 18, 2018Response Requested. (Due October 18, 2018)
Sep 20, 2018Motion to extend the time to file a response from October 18, 2018 to November 17, 2018, submitted to The Clerk.Sep 20, 2018Motion to extend the time to file a response is granted and the time is extended to and including November 19, 2018
Nov 19, 2018Brief of respondents Sanofi, et al. in opposition filed.Dec 4, 2018Reply of petitioners Amgen Inc., et al. filed. (Distributed)Dec 5, 2018DISTRIBUTED for Conference of 1/4/2019.
Jan 7, 2019Petition DENIED.
Recommended Citation: Amgen Inc. v. Sanofi, SCOTUSblog, https://www.scotusblog.com/cases/amgen-inc-v-sanofi/